

Co-morbid disease condition	Metformin		GLP-1 analogs	DPP-4 inhibitors	Insulin	Acarbose	Glitazones	SU	Glinides	Glycaemic control
Obesity (<i>BMI > 30 kg/m²</i>)	yes		yes	yes	O	yes	O	O	O	yes
Albuminuria (<i>>20 mg/g creatinine</i>)	O		O	O	O	O	O	O	O	yes
Impaired renal function (<i>GFR < 60 ml/min</i>)	no		(O) ²	(O) ²	yes	(O) ²	yes	(O) ²	yes	yes
Diabetic retinopathy (<i>Proven by fundoscopy</i>)	O		O	O	O	O	O	O	O	yes
Cardiovascular disease (<i>CAD, AMI, PCI, CABG</i>)	(yes) ³		(yes) ⁴	(yes) ⁴	(yes) ³	yes	(yes) ⁴	O	O	O
Cerebrovascular disease (<i>Stroke</i>)	(yes) ⁵		(yes) ⁴	(yes) ⁴	(yes) ³	yes	(yes) ⁴	O	O	O
Systolic heart failure (<i>EF <50%; NYHA ≥ II</i>)	(yes) ⁶	(no) ⁷	(yes) ⁴	(yes) ⁴	(O) ³	yes	no	O	O	O
Liver dysfunction	(yes) ⁸	(no) ⁹	O	O	O	O	O	no	no	O
Severe hypoglycaemia ¹ (<i>> 1/yr with 3rd party assistance</i>)	yes		(yes) ⁴	(yes) ⁴	O	yes	yes	O	O	O
Hospitalized patients	O ¹⁰		O	O	yes	O	O	O ¹⁰	O	O
Elderly (<i>> 65 years</i>)	yes		(yes) ⁴	(yes) ⁴	(yes) ³	O	O	O	O	O

Legend	recommended			neutral			contraindicated		
	yes		(yes)	O		(O)	(no)	no	

¹ requiring third party assistance; ² contraindicated Acarbose < 25 ml/min, DPP-4 < 50 ml/min, Exenatide < 30 ml/min, Liraglutide < 60 ml/min, SU < 30 ml/min; ³ only in those without hypoglycaemia; ⁴ no clear consensus because of a lack of data; ⁵ Metformin contraindicated within 2 weeks after stroke; ⁶ Metformin recommended in those with NYHA class I-II heart failure; ⁷ contraindicated in those with NYHA class III-IV heart failure; ⁸ Metformin recommended in hepatopathy without liver failure; ⁹ Metformin is contraindicated for patients with advanced liver failure; ¹⁰ Metformin and SU should be stopped if fasting periods or radiological contrast studies are envisioned